Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
319 hedge funds and large institutions have $6.04B invested in Blueprint Medicines in 2024 Q3 according to their latest regulatory filings, with 55 funds opening new positions, 141 increasing their positions, 83 reducing their positions, and 39 closing their positions.
76% more call options, than puts
Call options by funds: $218M | Put options by funds: $124M
70% more repeat investments, than reductions
Existing positions increased: 141 | Existing positions reduced: 83
41% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 39
5% more funds holding
Funds holding: 305 → 319 (+14)
2.81% less ownership
Funds ownership: 105.94% → 103.12% (-2.8%)
15% less capital invested
Capital invested by funds: $7.15B → $6.04B (-$1.11B)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$72.4M |
| 2 |
BlackRock
New York
|
+$46.9M |
| 3 |
State Street
Boston,
Massachusetts
|
+$38.3M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$30.4M |
| 5 |
ClearBridge Investments
New York
|
+$25.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$168M |
| 2 |
Holocene Advisors
New York
|
-$92M |
| 3 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$54.2M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$54.1M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$48.3M |
BPMC Hedge Fund Activity: Q3 2024 in Review
319 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q3 2024, worth a combined $6.04B — down 15% from $7.15B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new BPMC positions and 39 closed out — a net gain of 16 holders — while 141 added to existing stakes and 83 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $72.4M. The largest seller was Rock Springs Capital Management, cutting an estimated $168M.
- 319 institutional investors held Blueprint Medicines (BPMC) as of Q3 2024, up from 305 in Q2 2024.
- Funds reported $6.04B of Blueprint Medicines stock for Q3 2024, down 15% quarter-over-quarter.
- 55 funds opened new Blueprint Medicines positions in Q3 2024 and 39 closed out, a net change of +16 holders.
- The largest Blueprint Medicines buyer in Q3 2024 was Wellington Management Group, an estimated $72.4M added.
- The largest Blueprint Medicines seller in Q3 2024 was Rock Springs Capital Management, an estimated $168M sold.
Based on aggregated 13F filings for Q3 2024.